Eisai/Biogen Announced New Study Results of Lecanemab for Alzheimer’s Disease
- Why Lecanemab’s Adoption Faces an Uphill Battle in US?
- Yogurt and High LDL Cholesterol: Can You Still Enjoy It?
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
Eisai/Biogen Announced New Study Results of Lecanemab for Alzheimer’s Disease
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Eisai/Biogen Announced New Study Results of Lecanemab for Alzheimer’s Disease.
On April 27, Eisai issued a press release stating that it has published an article on long-term health outcomes using simulation modeling with the Aβ antibody Lecanemab in patients with early Alzheimer’s disease (AD) in Neurology and Therapy.
The results suggest that Lecanemab may slow the rate of AD progression, allowing treated patients to remain in the early stages of AD-induced mild cognitive impairment (MCI) for longer.
Based on data from the Phase IIb clinical trial (BAN2401-G000-201) evaluating the efficacy and safety of Lecanemab and published literature, we used disease models to predict and compare the presence of amyloidosis with Lecanemab plus standard of care (SOC) versus SOC alone. Long-term clinical outcomes in patients with early AD.
The results showed that compared with SOC, the lifetime risk of disease progression to mild, moderate and severe AD in the Lecanemab+SOC group may be reduced by 7%, 13% and 10%, respectively; patients in the Lecanemab treatment group developed mild, moderate and severe AD.
The mean duration of severe AD was prolonged by 2.51 years (3.10 vs 5.61 years), 3.13 years (6.14 vs 9.27 years), and 2.34 years (9.07 vs 11.41 years).
The study also showed that the earlier Lecanemab treatment was started, the greater the potential impact on disease progression. In a subgroup analysis, the incremental mean time to transition to mild and moderate AD dementia was 2.53 and 3.34 years, respectively, when treating MCI caused by AD compared with SoC.
Eisai/Biogen Announced New Study Results of Lecanemab for Alzheimer’s Disease
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.